Attrition rates are high during the early stages of biopharmaceutical development which impacts the cost and time to first in human studies. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to optimize for clinical success. As protein therapeutics become more complex,  the use of early stage in vitro expression to assess and identify product and manufacturing risks enable the development of process strategies to mitigate these threats as early as possible and maximize the outcome of development efforts. Early genetic assessment of expression cell lines can support cell line characterisation and can help to confirm identify stability concerns at an early stage

This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate. 

Featured Speaker

Rebecca Michael, PhD

Senior Group Leader, Cell and Molecular Biology Group
Lonza

Obtained PhD in Protein Chemistry/Engineering from University of Bath in 2002. Currently Senior Group Leader of the Cell and Molecular Biology Group in the Applied Protein Services (APS) Department. I have  22 years’ lab experience including 13 years’ experience in molecular biology, protein expression, purification and characterisation at Lonza.

NOW AVAILABLE ON-DEMAND

Register now for this webinar